In addition to inhibiting Treg function and restoring co-stimulatory signals from antigen-presenting cells, anti-CTLA-4 antibodies promote sustained activation of CD4+ and CD8+ effector T cells [59] and mediate-Fc-dependent depletion of CTLA-4high Tregs specifically within the tumor microenvironment [51]. This evidence concerns the gene CTLA4 and neoplasm.